Sum, it is good to hear from you.
You are reading the tea leaves like some others on the board. This month, all participants in the trial will have celebrated a second anniversary in the 2-73 testing; some have been in for 33 months. Anavex has info/data of at least 9 months on everyone in the new trial with new baselines and 21 months overall.
As to Klamer's talk at CNS conference, I recall the first news of his talk had Alzheimer's along with Rett and PD as the diseases he would discuss. Then, MS was added and Alzheimer's was removed. I thought there a reason for the removal, possibly that he could not touch the subject without revealing something that is material, like "... Anavex have a deal with the Aussie government to be announced later this month" or he would have to lie, which one never wants to do. Therefore, Alzheimer's was removed as a discussion topic to avoid that pitfall.
I think you are on to something, Sum, and maybe Dr. M is in Australia, not Boston. Boston comes later on the MTA's birth date, September 28th, I believe.
News 
Market Data 
Discover 
